Scholarlink

<p>Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of antineoplastic therapy despite major advances in antiemetic management. The introduction of serotonin (5-HT3) and neurokinin‑1 (NK1) receptor antagonists has significantly improved control rates, although underutilization of guideline-based prophylaxis persists. Current recommendations emphasize tailoring therapy to the emetogenic potential of agents, with olanzapine now incorporated for improved delayed-phase control. Challenges remain in breakthrough and delayed CINV, steroid-sparing regimens, and individualized risk-adapted prophylaxis. Optimizing adherence to ASCO, NCCN, and MASCC/ESMO guidelines and patient education are key to enhancing outcomes and quality of life during chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antiemetic therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Georg Jeryczynski

摘要

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of antineoplastic therapy despite major advances in antiemetic management. The introduction of serotonin (5-HT3) and neurokinin‑1 (NK1) receptor antagonists has significantly improved control rates, although underutilization of guideline-based prophylaxis persists. Current recommendations emphasize tailoring therapy to the emetogenic potential of agents, with olanzapine now incorporated for improved delayed-phase control. Challenges remain in breakthrough and delayed CINV, steroid-sparing regimens, and individualized risk-adapted prophylaxis. Optimizing adherence to ASCO, NCCN, and MASCC/ESMO guidelines and patient education are key to enhancing outcomes and quality of life during chemotherapy.